MOLINA ARTURO MD

PTGX CMO Arturo Molina sold 15,000 shares at $104.79 on 2026-03-26 (~$1.6M), retaining 84.1K shares.

Molina sold 15,000 shares at $104.79, near the 52-week high of $104.31, while retaining substantial holdings of 84.1K shares post-transaction. His cross-ticker track record shows a 90d well-timed rate of 83.33% across 10 prior sells, suggesting consistent skill in exit timing. However, his PTGX-specific history presents a contrasting picture: prior sales on 2026-01-27, 2026-01-26, 2026-01-23, and 2026-01-20 all saw positive 30-day returns (+7.8%, +5.9%, +0.4%, +0.7% respectively), indicating those exits preceded gains rather than declines; only 1 of 1 measurable PTGX sales achieved well-timed outcomes at the 90-day mark. The company's fundamentals remain challenged with annual revenue growth of -89.4%, $-39.3M net income, and $4.7M latest quarterly revenue, despite a $6.3B market cap. This sale pattern—repeated exits near highs combined with deteriorating fundamentals—merits scrutiny given the divergence between cross-ticker timing acumen and PTGX-specific execution outcomes.

CMO Molina sells 23,151 shares at $82.30 avg; holds 84,115 shares post-sale, paring stake by 21.6%

Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, executed 3 separate sales totaling 23,151 shares for $1,905,305.42 across three trading days (2026-01-23 to 2026-01-27), reducing his holdings by 21.6% from 107.3K to 84.1K shares. His same-ticker history shows mixed outcomes: 3 of 4 prior measurable sales at PTGX were well-timed at the 90-day mark, suggesting tactical execution consistency. The current stock price of $83.08 is only 0.78 above the blended sale average of $82.30, indicating the sales occurred near recent market levels. The company shows high-growth fundamentals (+624.1% annual revenue growth) but significant losses (-$39.3M net income on $4.7M quarterly revenue) and an elevated valuation (P/E 113.81), creating tension between growth narrative and profitability metrics. The sale magnitude and timing warrant monitoring of whether this reflects systematic rebalancing or a shift in executive positioning relative to near-term company prospects.

CMO Molina sells 9,514 shares (9.5K) of PTGX at $82.48; 4 of 5 prior sells at this ticker well-timed at 90 days.

Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, sold 9,514 shares at $82.48, reducing holdings by 8.9% to 97,266 shares post-transaction. This sale pattern aligns with his demonstrated execution at PTGX: 4 of 5 prior sales at this ticker were well-timed at the 90-day mark (stock declined after the sale). His cross-ticker track record shows a 83.33% well-timed rate on prior sells with an average 90-day return of -9.5%, reinforcing a consistent pattern of selling before declines. Against the company's fundamentals—$4.7M quarterly revenue, -$39.3M net loss, and 624.1% annual revenue growth—the insider appears to be executing sales strategically, though the current stock price of $83.89 is 12.0% below the 52-week high of $95.35, consistent with the recent -4.0% deterioration over the past 30 days.

CMO Molina sells 20,000 shares ($1.1M) over 2 days at $55.51–$57.03; 4 prior PTGX sells all well-timed (90d negative returns); stock down 7.4% from 52-week high.

Molina executed 2 separate sales totaling 20,000 shares for $1,125,400.00 on 2025-06-09 and 2025-06-10, reducing his holdings by 19.3%. His timing pattern at PTGX is notable: 4 of 4 prior sells were well-timed at the 90-day mark, with negative average 90-day returns of -0.7%, -21.2%, -21.7%, and -21.0%. The current sale occurred at an elevated price ($56.27 blended average) versus the current price of $55.34, just 7.4% below the 52-week high of $59.76. The company carries a negative quarterly net income of $-11.7M against revenue of $28.3M, with a high P/E of 60.81 despite strong annual revenue growth of 624.1%. This sale aligns with the insider's established pattern of well-timed exits at PTGX and warrants tracking of near-term price action to assess whether this trade precedes additional weakness.

CMO Molina sells 30,514 shares of PTGX for $1.7M at $55.74; 3 prior PTGX sells all well-timed at 90-day mark (-21.0 to -21.7% thereafter).

Arturo Molina, Chief Medical Officer, sold 30,514 shares for $1.7M on 2025-03-13 at $55.74, reducing holdings by 26.7% to 83.9K shares. His prior three open-market sales at PTGX (all in November 2024) each showed negative 90-day returns ranging from -21.0% to -21.7%, with a 100.0% well-timed rate across all three trades at the ticker level—a pattern suggesting consistent prescience in sell timing. His cross-ticker track record likewise shows a 90d well-timed rate of 100.00% across 3 prior sells, with a -21.3% average 90-day return, establishing a strong historical precedent for identifying deterioration windows. The current price of $54.78 is -8.3% from the 52-week high of $59.76 and follows a +46.4% surge over 30 days, creating a timing context where a CMO's sale at an elevated price after steep momentum gains merits investor attention given his demonstrated execution pattern.

CMO Molina sells 31,529 shares in 3 transactions (Nov 26–27) for $1,414,402.40, reducing stake by 40.4% to 46,444 shares

Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, executed 3 separate sales totaling 31,529 shares for $1,414,402.40 between November 26–27, 2024, at prices ranging from $44.50 to $45.60 (blended average $44.86). This represents a 40.4% reduction in his holdings from 77,973 shares to 46,444 shares. The scale and tempo of this exit—31.5K shares divested over two trading days near the stock's 52-week high of $48.43—stands against the company's current operational profile: PTGX generated $4,675,000.00 in quarterly revenue while posting a net loss of $33,210,000.00, and remains unprofitable on an annual basis despite 125.7% revenue growth. The sale occurred while the stock trades near its 52-week extremes, warranting assessment of whether this reflects constrained liquidity needs, portfolio rebalancing at an elevated valuation, or other material context not disclosed in the filing.